Charming Medical Limited Class A Ordinary Shares

NASDAQ:MCTA

Medical - Care Facilities

Healthcare
$29.36 +0.00%

+$0.00 today

Market cap
$445.55M
Beta
0.00
P/E (TTM)
414.6
EPS (TTM)
$0.07
52W Low $4.30High $31.70

Volume 0.00M

Average 0.87M

MCTA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA

Research & Development · FY2024 · year ended Mar 2025

Research & development remains negative

FY2024 research & development was $0, compared with $0 a year earlier.

Context

  • Research & development amounted to 0.0% of revenue in FY2024, unchanged from a year earlier.
  • Research & development increased in 0 of the last 2 fiscal years.
  • FY2024 was the highest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Last fiscal yearMar 2025
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2024
0 USD
Year-over-year change
—

Research & Development vs competitors

How MCTA compares with its peers on the latest reported figures

  • MCTA's FY2024 research & development of $0 is the 7th highest of the 10 companies compared; the peer median is $9.34M.
  • Research & development amounts to 0.0% of revenue for MCTA, versus a peer median of 1.4%.
MCTA Competitors Peer median
Research & Development for MCTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$172.31M +17.5%+18.0%—
RXSTRxSight, Inc.LTM Mar 2026$37.65M +2.6%+14.1%29.5%
DCTHDelcath Systems, Inc.LTM Mar 2026$34.06M +124.4%+16.3%37.7%
TCMDTactile Systems Technology, Inc.LTM Mar 2026$9.52M +12.9%+6.2%2.8%
SLPSimulations Plus, Inc.LTM Feb 2026$9.34M +29.5%+29.0%11.6%
NAKANakamoto Inc.LTM Mar 2026$4 -100.0%—0.0%
MCTACharming Medical Limited Class A Ordinary SharesFY2024$0 ——0.0%
AGLAgilon Health, Inc.LTM Mar 2026$0 ——0.0%
TOIThe Oncology Institute, Inc.LTM Mar 2026$0 ——0.0%
CCRNCross Country Healthcare, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding MCTA) $9.34M+15.2%+16.3%1.4%

Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
Revenue3.53M6.02M6.22M
Cost of Revenue2.04M2.1M2.04M
Gross Profit1.49M3.91M4.18M
Gross Margin42.3%65.1%67.2%
Research & Development000
Selling, General & Admin1.66M2.35M2.32M
Operating Expenses2.02M2.91M2.79M
Depreciation & Amortization211.08K391.7K263.45K
EBITDA(189.13K)1.42M1.72M
EBITDA Margin-5.4%23.6%27.6%
Operating Income(521.34K)1.01M1.39M
Operating Margin-14.8%16.8%22.3%
Interest Income10.29K19.51K64.14K
Interest Expense20.26K26.05K20.87K
Other Income / Expenses100.87K(5.35K)46.23K
Income Before Tax(420.47K)1M1.44M
Pre-Tax Margin-11.9%16.7%23.1%
Income Tax Expense(84.86K)181.75K236.08K
Net Income(305.12K)777.81K1.2M
Net Margin-8.6%12.9%19.3%
EPS (Basic)(0.02)0.050.07
EPS (Diluted)(0.02)0.050.07
Weighted Avg Shares16.94M16.94M16.94M
Weighted Avg Shares (Diluted)16.94M16.94M16.94M

Charming Medical Limited Class A Ordinary Shares

NASDAQ:MCTA

Intrinsic Alpha fair value

Locked

Current Price

$29.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.